Genmab shares slide after Roche dumps collaboration

Shares of Genmab skidded down about 10 percent this morning as investors got a chance to register their concern about Roche's announcement late Friday that it is exiting a deal to develop an antibody now in mid-stage trials.

Roche chalked up its decision to drop its support for RG1507--which targets IGF-1R--after scrutinizing the available data, other programs in the same field and the pharma company's portfolio priorities. Researchers had been studying RG1507 as a potential new therapy for sarcoma, non-small cell lung cancer and other oncology uses. Danish brokerage Jyske Bank said the news wasn't good for the Copenhagen-based biotech, but added that it had already discounted the program's limited value in considering Genmab's share potential.

"Despite this setback, Roche and Genmab continue to have a strong working relationship, with one shared aim of developing and providing novel efficacious agents to the patients that need them," said Lisa Drakeman, Ph.D., the CEO of Genmab.

- here's the Genmab release
- read the piece from Dow Jones
- check out the Reuters story

Suggested Articles

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…

Antibe's lead drug beat placebo at reducing osteoarthritis pain, boosting its case as an alternative to NSAIDs, commonly used to treat the condition.

The trial marks the start of a new phase of the response to SARS-CoV-2 in which people will receive drugs designed specifically for the virus.